David Quartermain

Immunotherapy Targeting Pathological Tau Conformers in a Tangle Mouse Model Reduces Brain Pathology with Associated Functional Improvements

Ayodeji A. Asuni, Allal Boutajangout, David Quartermain et al. · Journal of Neuroscience · 2007 · 501 citations · Full text

Transgenic Mouse Models, Tau Pathology, Immunology +22

Immunotherapy Targeting Pathological Tau Prevents Cognitive Decline in a New Tangle Mouse Model

Allal Boutajangout, David Quartermain, Einar M. Sigurdsson · Journal of Neuroscience · 2010 · 273 citations · Full text

Immunology, Immunodominance, Neurochemical Biomarkers +24

Acute but not chronic activation of the NMDA-coupled glycine receptor with D-cycloserine facilitates learning and retention

David Quartermain, Jay Mower, Michael Rafferty et al. · European Journal of Pharmacology · 1994 · 190 citations

D-cycloserine Facilitates, Molecular Physiology, Chronic Activation +9

Norepinephrine Biosynthesis Inhibition: Effects on Memory in Mice

Clark T. Randt, David Quartermain, Menek Goldstein et al. · Science · 1971 · 172 citations

Norepinephrine Biosynthesis Inhibition, Neuropsychology, Inhibitor Coincide +15

Blocking the apolipoprotein E/amyloid-β interaction as a potential therapeutic approach for Alzheimer's disease

Martin Sadowski, Joanna Pankiewicz, Henrieta Scholtzova et al. · Proceedings of the National Academy of Sciences · 2006 · 160 citations

Neuroinflammation, Alzheimer's Disease, Degenerative Pathology +17